Acrobiosystems for English
icon_bulk_orderBulk inquiry/Quick order
There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > Integrin alpha 4 beta 7

Integrin alpha 4 beta 7

Brief Information

Name:Integrin alpha-4/beta-7
Target Synonym:LPAM-1,Lymphocyte Peyer s patch Adhesion Molecule 1
Number of Launched Drugs:3
Number of Drugs in Clinical Trials:7
Lastest Research Phase:Approved

Product ListCompare or Buy

By Product Status:
By Product Category:
By Species:
By Tag:
By Conjugate:
Cat. No. Species Product Description Structure Purity Feature
IT7-H52W4 Human Human Integrin alpha 4 beta 7 (ITGA4&ITGB7) Heterodimer Protein, His Tag&Tag Free (MALS verified)
ACRO Quality

Part of Bioactivity data

Integrin alpha 4 beta 7 MALS images

The purity of Human ITGA4&ITGB7 Heterodimer Protein, His Tag&Tag Free (Cat. No. IT7-H52W4) is more than 85% and the molecular weight of this protein is around 210-250 kDa verified by SEC-MALS.

 Integrin alpha 4 beta 7 ELISA

Immobilized Human ITGA4&ITGB7 Heterodimer Protein, His Tag&Tag Free (Cat. No. IT7-H52W4) at 2 μg/mL (100 μL/well) can bind Monoclonal Anti-Human ITGA4&ITGB7 Antibody, Human IgG4 with a linear range of 0.1-2 ng/mL (QC tested).

Synonym Name

Integrin alpha 4 beta 7,ITGA4&ITGB7


Integrin alpha 4 beta 7 is an integrin family adhesion receptor that shares subunits with alpha 4 beta 1 (VLA4) and the E-Cadherin receptor, alpha E beta 7 . Integrin alpha 4 beta 7, which is critical for homing to intestinal mucosa, is induced during T cell activation in Peyer’s patches or mesenteric lymph nodes.Its expression requires signals from local dendritic and stromal cells, including secreted retinoic acid. The HIV-1 envelope protein gp120 binds to the active form of Integrin alpha 4 beta 7, and this may or may not account for the concentration of HIV-1 virus in the gut-associated lymphoid tissue (GALT). Integrin  alpha 4 beta 7 may also be involved in lymphocyte trafficking in acute intestinal graft vs. host disease (GVHD).

Clinical and Translational Updates

Public Drug Information

Name Research Code Research Phase Company First Brand Name First Approved Country First Indication First Approved Company First Approved Date Indications Clinical Trials
Carotegrast methyl AJM-300 Approved Ea Pharma, Eisai Co Ltd Carogra Japan Colitis, Ulcerative Ea Pharma Co Ltd 2022-03-28 Colitis, Ulcerative Details
Vedolizumab MLN-0002; LPD-02; MLN-002; MLN-02; LDP-02 Approved Millennium Pharmaceuticals Inc 安吉优, Entyvio United States Colitis, Ulcerative; Crohn Disease Takeda Pharmaceuticals U.S.A. Inc 2014-05-20 HIV Infections; Acquired Immunodeficiency Syndrome; Solid tumours; Inflammatory Bowel Diseases; Pediatric Crohn's disease; Pouchitis; Colitis; Celiac Disease; Cholangitis, Sclerosing; Pediatric ulcerative colitis; Colitis, Ulcerative; Urogenital Neoplasms; Crohn Disease; Melanoma; Carcinoma, Non-Small-Cell Lung Details
Natalizumab BG-0002; TY-21.6; AN-10022; BG-00002; AN-100226; BG-0002-E Approved Biogen Inc, Perrigo Llc Tysabri, Antegran, Antegren United States Crohn Disease; Multiple Sclerosis Biogen (Denmark) A/S 2004-11-23 Multiple Sclerosis, Relapsing-Remitting; Epilepsies, Partial; Arthritis, Rheumatoid; Graft vs Host Disease; Stroke; Multiple Sclerosis, Chronic Progressive; Multiple Sclerosis; Multiple Myeloma; Demyelinating Diseases; Myositis, Inclusion Body; Crohn Disease Details

Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
Etrolizumab PRO-145223; rhuMAb-Beta7; R-7413; RG-7413 Phase 3 Clinical Genentech Inc Colitis, Ulcerative; Crohn Disease Details
PTG-100 PTG-100 Phase 1 Clinical Protagonist Therapeutics Inc Celiac Disease; Colitis, Ulcerative Details
ABBV-382 Phase 1 Clinical Abbvie Inc HIV Infections Details
PN-10943 PN-10943-A; PN-10943; PN-943 Phase 2 Clinical Protagonist Therapeutics Inc Colitis, Ulcerative Details
Natalizumab biosimilar (Polpharma Biologics) PB-006 Phase 3 Clinical Polpharma Biologics Sa Multiple Sclerosis, Relapsing-Remitting Details
GS-1427 GS-1427 Phase 1 Clinical Gilead Sciences Sl Inflammatory Bowel Diseases Details
MORF-057 MORF-057 Phase 2 Clinical Morphic Therapeutic Inc Inflammatory Bowel Diseases; Colitis, Ulcerative Details

This web search service is supported by Google Inc.

Call us
Call us
North America:
+1 800-810-0816 (Toll Free)
Asia & Pacific:
+86 400-682-2521
+1 888-377-6111
1 Innovation Way, Newark, DE 19711, USA

Leave a message